Verastem Inc (VSTM)

Jun 10, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 10, 2025

Jun 06, 2025

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN

Jun 06, 2025

Jun 03, 2025

ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech

Jun 03, 2025

Jun 03, 2025

Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria

Jun 03, 2025

Jun 02, 2025

Transcript : Verastem, Inc.Special Call - marketscreener.com

Jun 02, 2025

Jun 02, 2025

What's Going On With Verastem Oncology Stock On Monday? - Benzinga

Jun 02, 2025

Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus

Jun 02, 2025

Jun 02, 2025

Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus

Jun 02, 2025

Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace

Jun 02, 2025

Jun 02, 2025

Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria

Jun 02, 2025

May 29, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

May 29, 2025

May 28, 2025

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - sharewise

May 28, 2025

May 28, 2025

Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News - GuruFocus

May 28, 2025

May 28, 2025

Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire

May 28, 2025

May 28, 2025

Verastem stock soars to 52-week high, hits $8.5 By Investing.com - Investing.com South Africa

May 28, 2025

May 27, 2025

Verastem stock soars to 52-week high, hits $8.5 - Investing.com Australia

May 27, 2025

May 27, 2025

US High Growth Tech Stocks to Watch in May 2025 - simplywall.st

May 27, 2025

May 26, 2025

VSTM Up As NDA For Ovarian Cancer Combo Gets FDA's Priority Review Tag - Barchart.com

May 26, 2025

May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail

May 24, 2025

May 23, 2025

Verastem (VSTM) Stock Price, News & Analysis - MarketBeat

May 23, 2025

May 23, 2025

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC - Yahoo Finance

May 23, 2025

May 23, 2025

Verastem Announces Positive RAMP 205 Trial Results - TipRanks

May 23, 2025

May 22, 2025

Verastem Oncology Announces Positive Updated Results from RAMP 2 - GuruFocus

May 22, 2025

May 22, 2025

Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News - GuruFocus

May 22, 2025

May 22, 2025

Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate - marketscreener.com

May 22, 2025

May 22, 2025

Verastem Oncology reports high response in pancreatic cancer trial By Investing.com - Investing.com Canada

May 22, 2025

May 22, 2025

Verastem Oncology reports high response in pancreatic cancer trial - Investing.com

May 22, 2025

May 22, 2025

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - FinancialContent

May 22, 2025

May 22, 2025

Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges - Investing.com

May 22, 2025

May 22, 2025

Verastem Inc (VSTM) Has Recovered 72.4% From Its Low: Is This The Beginning Of A Trend? - Stocksregister

May 22, 2025

May 21, 2025

Verastem CFO sells $90,592 in stock By Investing.com - Investing.com Nigeria

May 21, 2025

May 20, 2025

Tempus and Verastem partner on ovarian cancer diagnostic test By Investing.com - Investing.com South Africa

May 20, 2025

May 20, 2025

Verastem CFO sells $90,592 in stock - Investing.com

May 20, 2025

May 20, 2025

Tempus partners with Verastem for companion diagnostic development - Yahoo Finance

May 20, 2025

May 20, 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - 01net

May 20, 2025

May 20, 2025

Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - marketscreener.com

May 20, 2025

May 20, 2025

Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha

May 20, 2025

May 20, 2025

Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia

May 20, 2025

May 20, 2025

Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment - Stock Titan

May 20, 2025

May 20, 2025

The Manufacturers Life Insurance Company Makes New $74,000 Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 20, 2025

May 18, 2025

(VSTM) Investment Analysis - news.stocktradersdaily.com

May 18, 2025

May 17, 2025

Tower Research Capital LLC TRC Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 17, 2025

May 16, 2025

Stifel Financial Corp Grows Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 16, 2025

May 16, 2025

11,402 Shares in Verastem, Inc. (NASDAQ:VSTM) Purchased by Voya Investment Management LLC - Defense World

May 16, 2025

May 14, 2025

Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus

May 14, 2025

May 14, 2025

Verastem: Q1 Earnings Snapshot - Greenwich Time

May 14, 2025

May 14, 2025

Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus

May 14, 2025